Dignitas Founder Nicholas Delgado Sits Down With Paul Burton

Nicholas Delgado, founder and principal of Dignitas, an investment banking and advisory platform, sat down with ResQ Pharma, Inc’s CEO, Paul Burton for a wide-ranging conversation.


From growing up on the west side of Chicago to working in investment banking following law school, Paul Burton created waves in multiple industries before he was CEO of ResQ Pharma.

During his undergraduate studies at the University of Illinois at Chicago, Paul began working as a lab assistant in the pharmacology department and studied the tolerance of morphine. It was during this program that Paul excelled in his research and was exposed to all that is associated with a life science researcher. During this time he was also a cadet in the US Army, which would lead him to active duty during the Gulf War.

Upon returning to Chicago, he finished his second bachelor’s degree in English and then applied and was accepted to the University of Illinois at Urbana – Champaign College of Law. One year into his program, Paul was recruited to the MBA program. Through these programs, Paul joined multiple organizations, including the Black Law School Association.

“I was thinking that this venture would be a difficult and long process because of the industry it was in. I grew up in a modest household and had a view of the African American law students of being privileged and that we were not giving back to the community,” he said.

It was this observance that prompted Paul to organize several community service events in the inner cities of Chicago and promote interaction between other law students in different geographies.

Full Interview

RT Todd Beck @ToddBeck: In my spare time, I keep tabs on these #pharmaTech geniuses who are using sc…

RT Todd Beck @ToddBeck: In my spare time, I keep tabs on these #pharmaTech geniuses who are using science to prevent/reverse countless avoi…...

Thanks @CuresWReach ! From @lipidguy @SmartMoneyPaul @ToddBeck @AntoinetteGawin @thewizkid50 @paul…

Thanks @CuresWReach ! From @lipidguy @SmartMoneyPaul @ToddBeck @AntoinetteGawin @thewizkid50 @paulhertz...

RT Gareth Menagh @drgmenagh: Tricyclic Antidepressant Overdose in a Toddler Treated With Intravenous…

RT Gareth Menagh @drgmenagh: Tricyclic Antidepressant Overdose in a Toddler Treated With Intravenous Lipid Emulsion Dr Gareth Menagh -...

RT Gareth Menagh @garethmenagh: Lipid emulsion saves child’s life https://t.co/BCFEsKi0ct #Pediatric…

RT Gareth Menagh @garethmenagh: Lipid emulsion saves child's life https://t.co/BCFEsKi0ct #Pediatrics...

RT Dr. Guy Weinberg @lipidguy: Veterinary, equine lipid rescue. Lidocaine-induced asystolic arrest u…

RT Dr. Guy Weinberg @lipidguy: Veterinary, equine lipid rescue. Lidocaine-induced asystolic arrest unresponsive to epi and atropine. https://t.co/ohwzVk9woH...

Excellent podcast 30: Intravenous lipid emulsion for the treatment of drug toxicity https://t.co/ynv…

Excellent podcast 30: Intravenous lipid emulsion for the treatment of drug toxicity https://t.co/ynvnFPdLz5

Thanks @iBIOPROPEL ! https://t.co/3ZXFLAcGZc

Thanks @iBIOPROPEL ! https://t.co/3ZXFLAcGZc

RT BluePrint Orphan @BluePrintOrphan: ResQ Pharma granted #OrphanDrug status for #LipidRescue therap…

RT BluePrint Orphan @BluePrintOrphan: ResQ Pharma granted #OrphanDrug status for #LipidRescue therapy for local anesthetic systemic toxicity. Expect an N…...

RT Biotech 365 @Biotech365: ResQ Pharma Receives FDA Orphan Drug Designation for LipidRescue Therapy…

RT Biotech 365 @Biotech365: ResQ Pharma Receives FDA Orphan Drug Designation for LipidRescue Therapy https://t.co/kKuH952lWP #pharma #biotech #biopharma #science...

ResQ Pharma Receives FDA Orphan Drug Designation for LipidRescue™ Therapy for the Treatment of Local Anesthetic Systemic Toxicity

ResQ Pharma Receives FDA’s ODD status for LipidRescue Therapy (LRT) for LAST and on track to file NDA in first half of 2018